PMID- 36840811
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20240104
IS  - 1862-3514 (Electronic)
VI  - 18
IP  - 1
DP  - 2023 Feb 25
TI  - Zoledronic acid and denosumab for periprosthetic bone mineral density loss after 
      joint arthroplasty: a systematic review and meta-analysis of randomized 
      controlled trials.
PG  - 37
LID - 10.1007/s11657-023-01227-9 [doi]
AB  - OBJECTIVE: Periprosthetic bone mineral density (BMD) loss after total hip 
      arthroplasty (THA) may threaten the survival of implants. Zoledronic acid (ZA) 
      and denosumab were effective in reducing bone loss in conditions associated with 
      accelerated bone turnover by inhibiting osteoclast activity. This meta-analysis 
      aimed to assess the efficiency and safety of ZA and denosumab for periprosthetic 
      BMD loss after THA. METHODS: A systematic search of randomized controlled trials 
      (RCTs) associated with ZA or denosumab and THA was performed in MEDLINE, PubMed, 
      Embase, the Cochrane Central Register of Controlled Trials, and the Web of 
      Science from 1980 to 2022. Meta-analysis was performed by the Cochrane Review 
      Manager 5 (RevMan) version 5.41. Cochrane risk of bias tool and GRADEpro were 
      applied for methodological quality and overall evidence quality, respectively. 
      RESULTS: Nine RCTs involving a total of 480 patients were finally included and 
      analyzed. The pooled data that demonstrated significantly less periprosthetic BMD 
      loss in Gruen zone 7 occurred in the intervention group patients than in the 
      control group patients at 3 months (MD = 4.30, 95% CI: 1.78-6.82, P = 0.0008), 
      6 months (MD = 7.71, 95% CI: 5.41-10.02, P < 0.00001), and 12 months (MD = 8.19, 
      95% CI: 5.97-10.42, P < 0.00001) after THA. No serious adverse events (AEs) were 
      observed. CONCLUSION: In the current analysis with evidence on the efficacy and 
      safety of ZA and denosumab, the authors recommend the use of ZA or denosumab 
      treatment for periprosthetic bone mineral density loss. SYSTEMATIC REVIEW 
      REGISTRATION: PROSPERO registration number: CRD42022369273.
CI  - (c) 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis 
      Foundation.
FAU - Li, Xiao
AU  - Li X
AD  - Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, 
      China.
FAU - Han, Jingru
AU  - Han J
AD  - Department of Oncology, First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, China.
FAU - Shi, Xiaotong
AU  - Shi X
AD  - Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, 
      China.
FAU - Bi, Zhiguo
AU  - Bi Z
AD  - Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, 
      China.
FAU - Liu, Jianguo
AU  - Liu J
AD  - Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, 
      China. liujg6@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230225
PL  - England
TA  - Arch Osteoporos
JT  - Archives of osteoporosis
JID - 101318988
RN  - 6XC1PAD3KF (Zoledronic Acid)
RN  - 4EQZ6YO2HI (Denosumab)
RN  - 0 (Bone Density Conservation Agents)
SB  - IM
MH  - Humans
MH  - Zoledronic Acid
MH  - Bone Density
MH  - Denosumab
MH  - *Bone Density Conservation Agents/pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - *Arthroplasty, Replacement, Hip/adverse effects
OTO - NOTNLM
OT  - Denosumab
OT  - Meta-analysis
OT  - Randomized controlled trial
OT  - Systematic review
OT  - Total hip arthroplasty
OT  - Zoledronic acid
EDAT- 2023/02/26 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/25 11:21
PHST- 2022/11/03 00:00 [received]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/02/25 11:21 [entrez]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
AID - 10.1007/s11657-023-01227-9 [pii]
AID - 10.1007/s11657-023-01227-9 [doi]
PST - epublish
SO  - Arch Osteoporos. 2023 Feb 25;18(1):37. doi: 10.1007/s11657-023-01227-9.